News Article | February 20, 2017
Basel, Switzerland, February 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced its financial results for 2016 today with product sales from Cresemba® (isavuconazole) and Zevtera®/Mabelio® (ceftobiprole) of CHF 7.1 million in Europe, royalties on US Cresemba sales of CHF 7.3 million, total revenue of CHF 66.0 million, a year-end cash and financial investment position of CHF 289.0 million and a reduced operating loss of CHF 43.9 million. Basilea's CEO Ronald Scott said: "We've launched Cresemba addressing severe fungal infections in the first European markets and made substantial progress in the commercialization of both Cresemba and our antibiotic Zevtera/Mabelio. We are pleased to announce that we achieved sales for the full year of CHF 7.1 million in Europe. The Cresemba launch is also going well in the USA, where our license partner Astellas Pharma US reported 2016 sales of USD 46 million, on which we received CHF 7.3 million in royalties." He continued: "We plan to initiate a ceftobiprole clinical phase 3 development program under our agreement with BARDA in mid-2017 to support a potential future US regulatory filing and we continue to make good progress on our oncology development programs addressing tumor resistance. We were able to expand our BAL101553 oral phase 1/2a study to include brain cancer patients according to plan." Anti-infectives: Cresemba and Zevtera/Mabelio marketed by Basilea in first European countries with partnerships in place for important additional markets Basilea is marketing Cresemba and Zevtera/Mabelio in Germany, Italy, the UK, France and Austria; Zevtera is also marketed in Switzerland. Basilea's licensing partner Astellas Pharma US markets Cresemba in the United States. In 2016, Basilea entered into distribution agreements for isavuconazole and ceftobiprole with Grupo Biotoscana S.L. in nineteen Latin American countries and with Unimedic Pharma AB for the Nordics. The distribution agreement with Hikma Pharmaceuticals LLC for the Middle East and North Africa (MENA) region was extended to include isavuconazole in addition to ceftobiprole. In addition, Basilea concluded a license agreement with Asahi Kasei Pharma Corporation for the development and commercialization of isavuconazole in Japan. Basilea's existing partnerships cover more than forty countries around the world in addition to the countries that Basilea is directly serving. The latest guideline issued by the European Conference on Infections in Leukaemia (ECIL) recommends Cresemba for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. The guideline states that isavuconazole is as effective as voriconazole with a better safety profile.1 This recommendation in one of the most relevant treatment guidelines in Europe underscores the potentially important clinical role of Cresemba in the treatment of patients with these life-threatening infections. Contract with BARDA to support ceftobiprole phase 3 development for US market Basilea entered into a contract in 2016 with the Biomedical Advanced Research and Development Authority (BARDA) for the clinical phase 3 development of ceftobiprole to support a potential regulatory filing in the US, the largest market value-wise for branded hospital antibiotics. BARDA provides initial funding of approximately USD 20 million for the preparation of the phase 3 program. The total value of the BARDA contract could reach USD 100 million over a period of 4.5 years if pre-defined milestones are met. Basilea submitted clinical study protocols to the US Food and Drug Administration (FDA) for two phase 3 studies, one in Staphylococcus aureus bacteremia (SAB) and one in acute bacterial skin and skin structure infections (ABSSSI). Basilea will initiate the phase 3 clinical development program once it completes the FDA Special Protocol Assessment (SPA) process. Two oncology drug candidates in clinical development: tumor checkpoint controller BAL101553 and panRAF/SRC kinase inhibitor BAL3833 In 2016 Basilea further strengthened its oncology pipeline, the second pillar of its hospital-focused strategy, by broadening BAL101553's clinical development program. A separate study arm for patients with glioblastoma was added to the ongoing phase 1/2a clinical study with oral BAL101553, based data in preclinical glioblastoma tumor models demonstrating activity of the drug candidate in this often lethal brain cancer. Potential patient-selection biomarkers have also been identified and will be assessed in BAL101553-treated glioblastoma patients. In addition, a further phase 1/2a clinical study was initiated to explore continuous intravenous infusion. Dose-escalation in the phase 1 study with orally administered BAL3833 in patients with solid tumor cancers, including metastatic melanoma, is continuing with the aim to determine the maximum tolerated dose. Preclinical data on BAL3833 presented at the American Association for Cancer Research (AACR) annual meeting showed that the drug candidate has anti-cancer activity in KRAS-driven in vitro and in vivo tumor models via inhibition of the RAF and SRC family kinases. This indicates that BAL3833 may also be effective in non-melanoma KRAS-mutant cancers such as pancreatic, colorectal and non-small-cell lung cancer, potentially providing a new therapeutic option in these indications. Focus 2017 on growing product sales and progress in pipeline Basilea's CEO Ronald Scott stated: "In 2017, we expect to further grow our product sales as we continue to execute on our commercialization and partnering strategy. We anticipate seeing initial contributions from our current distributors as their first marketing authorizations are granted. We are also working towards further agreements with potential partners to cover remaining commercially relevant markets including Asia Pacific, Russia/CIS, and certain European countries. In addition, we anticipate that Swissmedic will complete its review of our isavuconazole marketing authorization application in 2017." He added: "An important goal for us this year is to finalize the Special Protocol Assessment process with the US FDA in order to start the clinical phase 3 program for ceftobiprole under our BARDA contract. Our initial focus will be on skin and bloodstream infections, two areas of high medical need." Ceftobiprole will have a total of ten years of market exclusivity in the US from potential approval based on its Qualified Infectious Disease Product designation granted by the FDA. Upon successful completion of the studies, the phase 3 data could be used to support supplemental marketing authorization applications for ceftobiprole in Europe and other territories, potentially resulting in label extensions for ceftobiprole. In 2017, Basilea will further advance the clinical development of its oncology drug candidates and expects to complete dose-escalation in BAL101553's phase 1/2a studies and BAL 3833's phase 1 study. Notes: Consolidated figures in conformity with US GAAP; rounding was consistently applied. The consolidated financial statements of Basilea Pharmaceutica Ltd. for the financial year 2016 can be found on the company's website at http://annualreport.basilea.com. Full-year product revenue 2016 amounted to CHF 7.1 million (2015: none). Contract revenue 2016 amounted to CHF 57.7 million (2015: CHF 51.2 million), including CHF 37.7 million (2015: CHF 37.6 million) related to the global agreement for Toctino® and CHF 19.3 million (2015: CHF 13.6 million) related to the license agreement with Astellas for isavuconazole. Total operating income in 2016 including sales amounted to CHF 66.0 million (2015: CHF 52.8 million). Research and development net expenses in 2016 amounted to CHF 48.4 million (2015: CHF 60.1 million) and were mainly related to activities for the phase 1/2a development of oncology drug candidate BAL101533, phase 1 clinical development of oncology drug candidate BAL3833, costs for the pediatric program for ceftobiprole and activities related to isavuconazole. The decrease of CHF 11.7 million as compared to 2015 is mainly due to 2015 isavuconazole pre-launch activities. Selling, general and administration expenses in 2016 amounted to CHF 56.1 million (2015: CHF 54.2 million), and included costs related to the commercialization of Cresemba and Zevtera/Mabelio and stock-based compensation of CHF 4.2 million (2015: CHF 4.6 million). In 2016, the operating loss was reduced by 29% to CHF 43.9 million from CHF 61.5 million in 2015 and net loss 2016 was reduced to CHF 51.3 million (2015: CHF 61.6 million), resulting in a lower basic and diluted loss per share of CHF 5.07 (2015: CHF 6.09). The net cash used for operating activities in 2016 amounted to CHF 75.0 million as compared to CHF 67.8 million in 2015. The increase in comparison to 2015 is mainly due to the milestone payment from Astellas in 2015 upon approval of isavuconazole in the US, which reduced the net cash used in the previous period. Combined cash and financial investments amounted to CHF 289.0 million as of December 31, 2016, compared to CHF 364.7 million as of December 31, 2015. Basilea continues to focus on growing sales of its two marketed products while at the same time advancing its clinical development pipeline. Basilea anticipates total annual product sales of approximately CHF 15 million in 2017, a more than 100% increase over 2016, and a participation in US sales through royalties of approximately CHF 14 million. Total operating expenses after anticipated BARDA reimbursements for 2017 are estimated at approximately CHF 10 million on average per month with an operating loss of approximately CHF 3 million on average per month. Cresemba (isavuconazole) - an i.v. and oral azole antifungal for the treatment of invasive mold infections Isavuconazole is an i.v. and oral azole antifungal and the active agent of the prodrug isavuconazonium sulfate. It is approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.2 In Europe, isavuconazole received marketing authorization for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.3 The European marketing authorization is valid in all 28 European Union (EU) member states, as well as in Iceland, Liechtenstein and Norway. Isavuconazole has orphan drug designation for the approved indications in Europe and the US. Basilea is marketing isavuconazole as Cresemba in Germany, Italy, the UK, France and Austria. In the United States Cresemba is marketed by Basilea's licensee Astellas Pharma US. Outside the US and the EU, isavuconazole is not approved for commercial use. The European Conference on Infections in Leukaemia (ECIL) recommends isavuconazole in its current guideline for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients.1 Zevtera/Mabelio (ceftobiprole) - a broad-spectrum antibiotic from the cephalosporin class for i.v. administration with bactericidal activity against certain Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp. Ceftobiprole (European trade name Zevtera or Mabelio, depending on the country) is approved for sale in 13 European countries and several non-European countries for the treatment of adult patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).4 Basilea is currently marketing the drug in Germany, Italy, the UK, France, Austria and Switzerland. Ceftobiprole received Qualified Infectious Disease Product (QIDP) designation from the US FDA for the potential treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). The drug is not approved in the United States. In 2016, Basilea entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the clinical phase 3 development of ceftobiprole to support a potential regulatory filing in the US. The total value of the BARDA contract could reach USD 100 million over a period of 4.5 years if pre-defined milestones are met. Initial studies are planned in acute bacterial skin structure infections (ABSSSI) and Staphylococcus aureus bacteremia (SAB). BAL101553 - a tumor checkpoint controller in phase 1/2a clinical testing in patients with advanced solid tumors including recurrent or progressive glioblastoma The small molecule oncology drug candidate BAL101553 (prodrug of BAL27862) is being developed as a potential therapy for diverse cancers, including tumor types unresponsive to standard therapeutics. The drug is currently undergoing clinical phase 1/2a evaluation (oral and continuous infusion) in patients with advanced solid tumors. In December 2016, the oral study was extended by adding a separate arm for patients with recurrent or progressive glioblastoma after prior radiotherapy. The drug candidate has shown evidence of clinical anti-tumor activity in a phase 1/2a study with weekly 2-hour i.v. infusion, during which the maximum tolerated dose and the recommended phase 2 dose for this administration regimen was established.5 BAL3833 (also known as CCT3833) is an orally administered small-molecule panRAF/SRC kinase inhibitor targeting cell proliferation signaling pathways that are associated with tumor growth and resistance development to current therapies. It is the lead compound of a series of kinase inhibitors in-licensed by Basilea in April 2015 under an agreement with The Institute of Cancer Research, Cancer Research Technology, the Wellcome Trust, and The University of Manchester. BAL3833 is currently being investigated in a phase 1 study in adult patients with advanced solid tumors including metastatic melanoma. The compound originates from the renowned UK cancer research institution, The Institute of Cancer Research, where it was developed by scientists funded by Cancer Research UK and the Wellcome Trust. Basilea Pharmaceutica Ltd. invites you to participate in a conference call on Monday, February 20, 2017, 4 p.m. (CET), during which the company will discuss today's press release. A playback will be available 1 hour after the conference call until Wednesday, February 22, 2017, 6 p.m. (CET). Participants requesting a digital playback may dial: and will be asked to enter the ID 19991 followed by the # sign. The shareholders of Basilea Pharmaceutica Ltd. are informed that the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd. for the business year 2016 will take place on Thursday, April 27, 2017 at 2 p.m. at the Radisson Blu Hotel in Basel, Switzerland. The invitation will be published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt, SHAB). Shareholders who are recorded in the share register with voting rights on April 13, 2017 will be entitled to participate and exercise their voting rights. Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address the medical problem of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com. This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: This press release can be downloaded from www.basilea.com. 1 F. Tissot et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2016 (101), published online ahead of print; www.haematologica.org/content/early/2016/12/20/haematol.2016.152900 [Accessed February 17, 2017] 2 Cresemba US prescribing information [Accessed: February 17, 2017] 3 European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: February 17, 2017] 4 UK Summary of Product Characteristics (SPC) Zevtera®: http://www.mhra.gov.uk/ [Accessed: February 17, 2017] 5 J. Lopez et al. Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors. American Society of Clinical Oncology (ASCO) annual meeting 2016, abstract 2525, poster board #225
News Article | February 22, 2017
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 22, 2017) - CRYSTAL EXPLORATION INC. (the "Company" or "Crystal") (TSX VENTURE:CEI) is pleased to report a series of results from Crystal's 100% owned Muskox and Hood Project areas. All the existing archived drill core has now been logged and sampled in a series of 7 composite samples from the Muskox Kimberlite. The results are summarized below in Table 1. The samples were processed using the Saskatchewan Research Councils ("SRC's") Dense Media Separation ("DMS") plant to recover commercial sized (approximately +0.85 mm), macro-diamonds. The combined grade from the DMS processing for the magmatic kimberlite samples is 0.45 carats per tonne ("cpt") and the combined grade from the DMS processing for the pyroclastic kimberlite samples is 0.19 cpt. The largest diamonds recovered include 0.49 carats, 0.40 carats and 0.30 carats (see diamond pictures below). The diamonds are described as off-white, transparent to translucent with minor inclusions. Caustic fusion was completed on two rock samples collected from the Muskox Kimberlite. The samples were mantle xenoliths and contained 7 diamonds and 45 diamonds respectively. The results are shown in Table 2. Caustic fusion was completed on two composite rock samples collected from the James River Kimberlite Dyke at surface, located at the Hood Project confirming it is diamondiferous and warrants further exploration. In total, 4 microdiamonds were recovered from sample 16DBP500. The James River Dyke is only 15km from the diamondiferous Tenacity Kimberlite. A high priority drill target developed by Crystal during 2016 exists along the structure that hosts the James River Kimberlite Dyke. The results are shown in Table 2. To view three images of Muskox diamonds, please visit the following link: http://media3.marketwire.com/docs/Muskox_Diamonds.pdf Jim Greig, President and CEO of Crystal Exploration Inc., commented, "The samples are similar to some of the historical results at the Muskox Kimberlite. The material processed was archived drill core from previous operators drill campaigns that enabled a cost-effective method to further examine the large kimberlite pipe which measures nearly 4 hectares at surface and extends to over 300m depth. The size and grade potential at Muskox has yet to be fully understood and is illustrated through various sampling programs that generated high to marginal grades throughout the years. The recent results reflect a very small sample size and it is the diamond valuation of good quality gemstones that needs further examination. Future exploration will be required to understand the entire diamond opportunity within the Muskox Kimberlite Pipe. Crystal's projects that neighbor the Jericho Diamond Mine may represent an opportunity for near-term production at an existing diamond mining facility." In addition, Mr. Anthony Jackson has been appointed Chief Financial Officer ("CFO") of Crystal, effective February 1, 2017. Mr. Jackson replaces Mr. Justin Bourassa, who has resigned as CFO of the Company. Mr. Bourassa was an integral part of the Crystal team and the Company wishes him well on all future endeavors. Crystal is a Canadian diamond exploration company with Common shares listed for trading on the TSX Venture Exchange. Crystal is backed by proven and seasoned resource sector professionals who have a track record of advancing exploration projects from grassroots through to production scenarios. The technical content of this news release has been reviewed and approved by Dean Besserer, P.Geol., the Technical Advisor of the Company and a Qualified Person as defined by National Instrument 43 -101. ON BEHALF OF THE BOARD OF DIRECTORS This press release contains "forward-looking information", as such term is defined in applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects", "believes", "anticipates", "budget", "scheduled", "estimates", "forecasts", "intends", "plans" and variations of such words and phrases, or by statements that certain actions, events or results "may", "will", "could", "would" or "might", "be taken", "occur" or "be achieved". Forward-looking information is based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which Crystal operates, are inherently subject to significant operational, economic and competitive uncertainties and contingencies. Crystal cautions that forward-looking information involves known and unknown risks, uncertainties and other factors that may cause Crystal's actual results, performance or achievements to be materially different from those expressed or implied by such information, including, but not limited to, factors discussed in each management discussion and analysis of the Company, available on SEDAR at www.sedar.com. Although Crystal has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information in this press release is made as of the date of this press release, and Crystal disclaims any intention or obligation to update or revise such information, except as required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
News Article | March 2, 2017
- SRC emite la declaración política a los líderes del G20 sobre los pilares fundamentales de defensa y fortalecimiento del programa de reforma global WASHINGTON, 2 de marzo de 2017 /PRNewswire/ -- El 27 de febrero de 2017, el Systemic Risk Council publicó una declaración política a los ministros de finanzas, gobernadores, jefe reguladores financieros y líderes del comité legislativo de los países del G20. "El SRC ha decidido poner en papel nuestra visión de los ingredientes esenciales de un sistema financiero sano y robusto," dijo Sir Paul Tucker, presidente de SRC. Declaró: "A raíz de los debates no resueltos a nivel global, los cambios potenciales a la política estadounidense sobre la estabilidad del sistema y problemas actuales en Europa, SRC está dispuesto a hacer comentarios específicos y recomendaciones para asegurar que las autoridades estén comprometidas en la construcción de un sistema financiero resistente." El Systemic Risk Council se fundó por el CFA Institute, una organización global de más de 147.000 profesionales de inversión que anteponen el interés de los inversores y establecen el estándar de excelencia profesional en finanzas. En su declaración, SRC subrayó la importancia vital de cinco pilares fundamentales del programa de reforma global: 1. encargando capital tangible común mucho mayor en grupos bancarios para reducir la probabilidad de fallos, con firmas individuales necesarias para llevar más capital de equidad, mayores consecuencias sociales y económicas de su crisis; 2. requiriendo intermediarios de tipo bancario para reducir significativamente su exposición al riesgo de liquidez; 3. empoderando a los reguladores a adoptar una visión de todo el sistema a través del cual puedan asegurar la resistencia de todos los intermediarios y las actividades de mercado, cualquiera que sea su tipo formal, que son materialmente relevantes a la resistencia del sistema como un todo; 4. simplificando la red de exposiciones entre intermediarios por mandatos que, siempre que sea posible, las transacciones de derivados estén centralmente liquidadas por contrapartes centrales que deben ser extraordinariamente resistentes; y 5. estableciendo regímenes mejorados para la resolución de intermediarios financieros de cualquier tipo, tamaño o nacionalidad para que, aun en medio de una crisis, se puedan mantener servicios esenciales para los hogares y empresas sin el apoyo de solvencia del contribuyente — un sistema de rescate de los poseedores de bonos en vez de rescate fiscal. El SRC aconsejó que este no es un momento para relajarse o para retirarse del programa de reforma global, dada la deuda de la proyección y la deteriorada capacidad de política macroeconómica para amortiguar choques a la recuperación continua. Por el contrario, este es un momento para la estabilidad del sistema financiero para seguir siendo una prioridad. El texto completo de la carta está disponible aquí http://www.systemicriskcouncil.org/wp-content/uploads/2017/02/Systemic-Risk-Council-Policy-Statement-to-G20-Leaders.pdf. El independiente, no partidista Systemic Risk Council (www.systemicriskcouncil.org) se formó para supervisar y fomentar la reforma de la reglamentación de Estados Unidos y mercados de capital mundiales, con un enfoque en el riesgo sistémico. SRC es financiado por el CFA Institute, una asociación global de más de 147.000 profesionales de inversión que anteponen los intereses de los inversores y el estándar de excelencia profesional en finanzas. SRC trabaja colaborativamente para buscar un acuerdo en cada una de sus recomendaciones. Las declaraciones, documentos y recomendaciones del sector privado, voluntarios de SRC no representan necesariamente las opiniones de CFA Institute. Presidente Emérito: Sheila Bair, Presidente del Washington College y expresidente de FDIC Baroness Sharon Bowles, exmiembro del Parlamento Europeo y expresidente del Comité de Asuntos Monetarios y Económicos del Parlamento William Donaldson, expresidente de la Comisión de Bolsa y Valores Jan Pieter Krahnen, presidente de Finanzas Corporativas en Goethe-Universität en Frankfurt y director del Centre for Financial Studies Chester Spatt, Tepper School of Business, Carnegie Mellon University, exdirector de Economía, Comisión de Bolsa y Valores Lord Adair Turner, expresidente de la UK Financial Services Authority y expresidente del Financial Stability Board's Standing Committee on Supervisory and Regulatory Cooperation Nout Wellink, exdirector general del Banco Central de los Países Bajos y expresidente del Basel Committee on Banking Supervision * Afiliaciones son para propósitos de identificación solamente. Los miembros de SRC participan como individuos y esta carta refleja sus propias opiniones y no las de las organizaciones con las cuales están afiliados.
News Article | March 2, 2017
SIG University, a comprehensive, online certification curriculum focused on strategic sourcing and governance practices and methodologies today announces the next start date for its Certified Sourcing Professional curriculum. The twelve-week Certified Sourcing Professional (CSP) course will be begin April 3. Closed cohorts are available for companies enrolling 25 or more students simultaneously. Discounts are also available for students and/or companies who enroll before March 6, 2017. SIG U was created at the request of SIG members, who saw an educational training gap in today's workforce. The SIG U learning model enhances experiential learning with best-practice training. It is delivered over a 12-week period in a virtual classroom and is facilitated by experienced practitioner faculty who currently hold executive leadership positions in the sourcing space. The certification, which is valid for five years, is delivered in a modular format with lessons, assessments and quizzes to test mastery of subject matter. In addition, SIG U students have access to one of the largest banks of available sourcing data in the U.S. through the SIG Resource Center (SRC), which houses over 5,000 tools, templates, methodologies, processes, whitepapers and archived presentations. “Our first year in operation provided us with so much momentum,” says Mark Pollack, SIG University Vice President. “Not only did we put hundreds of students through the program with overwhelmingly positive feedback, but also started our second year in business with our largest class ever.” Adds Dawn Tiura, SIG University President, "The number of companies putting their entire procurement departments through the program is amazing. They have validated that the effort we put in to developing the program is answering the need in the industry--so much so that we will launch a separate certification for Governance and Risk in late June to address another concern facing our members." About SIG University SIG University, http://www.siguniversity.org is the premier training and certification program for sourcing and outsourcing professionals looking to enhance their practical experience with the latest sourcing thought leadership. SIG University was founded on the ideals of elevating the sourcing profession to deliver strategic value to the corporation, and is the only sourcing and governance certification designed and delivered by seasoned sourcing practitioners. About SIG SIG, http://www.sig.org is a membership organization that provides thought leadership and networking opportunities to executives in sourcing, procurement and outsourcing from Fortune 500 and Global 1000 companies and the advisors who serve them. SIG is widely known as a forum for sharing “next” practices and thought leadership through live networking events, virtual forums and a comprehensive online SIG resource center (SRC), which was developed by and for professionals in sourcing and outsourcing. The organization is unique in that it blends practitioners, service providers and advisory firms in a non-commercial environment. SIG is also the parent organization for SIG University, a one-of-a-kind certification and training program for professionals and executives seeking deep expertise in sourcing and governance for themselves or their teams, as well as Outsource, which provides unrivaled digital content for the opinion-formers and decision-makers at the heart of the outsourcing space.
News Article | March 1, 2017
This SRC is the only meeting of its kind specifically dedicated to the field of photoreceptor biology. The scientific program reflects the multi-disciplinary nature of this field, encompassing classical biochemistry and structural biology as well as modern imaging techniques and molecular therapeutic approaches. Specific session topics will range from photoreceptor physiology and RPE cell biology to the immune respose to photoreceptor degeneration. The scientific program will include two keynote addresses and invited talks, as well as numerous short talks and DataBlitz presentations that will be selected from submitted abstracts. The meeting schedule and venue are designed to present the most exciting scientific advances in an atmosphere that encourages informal interactions and collaborations. All attendees will have the opportunity to present a poster, and optional recreational activities will be available to all participants to foster the exchange of ideas and formulate new collaborations.
News Article | February 22, 2017
DALLAS, Feb. 22, 2017 /PRNewswire/ -- Spirit Realty Capital, Inc. (NYSE: SRC) ("Spirit" or the "Company"), a premier net-lease real estate investment trust (REIT) that invests in single-tenant, operationally essential real estate, today announced that it has released its financial and oper...
News Article | March 1, 2017
Steroid hormone action impacts many aspects of physiology and disease states. Although scientists in the field traditionally focused on how nuclear steroid receptors mediate gene transcription, it is now established that these same receptors exist and function at various cellular locations including the cell membrane and mitochondria. Thus this conference focuses on the latest advances and approaches to understand how signaling from extra-nuclear and nuclear steroid receptors integrate to produce genomic and non-genomic biological effects. This year's SRC focuses on steroid hormone action in cancer, metabolism, neuroscience, cardiovascular effects, ion channels, lung disease. Many new speakers will give talks and the opportunity for trainees to present their work in oral and poster sessions will be emphasized as well. Most importantly, many productive collaborations between scientists, junior and senior, have occurred from the interactions during the meeting. Junior scientists and trainees are especially encouraged to interact with senior faculty, in multiple venues that encourage this during the meeting.
News Article | March 1, 2017
This SRC is focused on protein aggregation, which plays central roles in health and in disease and a converged understanding of these dual roles is absolutely essential if we are to understand the emergence of biological complexity and the onset and progression of devastating systemic and neurodegenerative diseases. Importantly, protein aggregation and aggregates are also central in numerous biological functions as is evidenced in the growing number of accounts of functional aggregates and their roles in fungi, bacteria, and in the innate immune system of humans. Recent studies have highlighted the role of phase separation driven by a form of protein aggregation that gives rise to functional, non-stoichiometric assemblies, known as membraneless organelles. The intent of this meeting is to bring together scientists working on biophysical and biological aspects of protein aggregation and connect physical understand of aggregation to its biological consequences in post mitotic cells. The conference will begin with keynote talks by two leading figures, Dr. Virginia Lee and Dr. Sheena Radford. Their talks will highlight the translational aspects and biophysical underpinnings of protein aggregation. The remainder of the conference will be organized around specific thematic sessions that focus on specific proteins or collections of proteins and work up to uncovering the impact of protein aggregation on cellular processes and disease states. This conference will span a range of topics. These include a discussion of emerging technologies to study protein aggregation in vitro and in cells, advancements in our understanding of cellular stresses induced by protein aggregation, our ability to target the stress response pathways therapeutically as a route to finding cures for devastating neurological and systemic diseases, routes that connect aggregation mechanisms and specific aggregates to disease, methods to target aggregation or particular species in order to cure disease, the emerging synergy between protein aggregation and phase separation in the context of form liquid-like membraneless bodies within cells, and the functional role of protein aggregates, a theme that continues to be paradigm shifting in biology. Taken together these sessions will give the participants an integrative view of protein aggregation and the impact it has on health and disease. The cross-disciplinary nature of the conference is accentuated by the program, which brings together biophysicists, structural biologists, and bioengineers with cell biologists and clinical scientists.
News Article | February 28, 2017
This SRC presents progress in research on diverse aspects of genetic recombination, a critical process that maintains integrity of the genome and that ensures the faithful transmission of the genome between generations. This conference focuses on the study of recombination mechanisms, the impact of recombination on genome integrity, and the influence of other DNA processes on recombination. Many of the recent advances in understanding recombination in normal, pathological, and environmentally stressed contexts have emerged through new combinations of experimental approaches spanning biochemistry, biophysics, genetics, genomics, and cytology. The agenda reflects the diversity of approaches currently used and is specifically geared toward identifying the emerging technologies and concepts that are moving the field forward. The meeting will focus on new, unpublished data in the field and will highlight connections between recombination and other cellular processes, including transcription, replication, cell cycle progression, and other branches of DNA repair. There will be presentations by researchers using diverse model organisms including bacteria, fungi, flies, nematodes, and mammalian cells, as well as in vitro biochemistry and structural biology. The meeting will foster collaboration between researchers worldwide who are interested in the basic and clinical aspects of recombinational repair, particularly in cancer biology. There will be many opportunities for interaction between established investigators and scientists who are new to the field, and a significant number of the plenary speakers will be chosen from submitted abstracts.
News Article | February 28, 2017
WASHINGTON, 28. Februar 2017 /PRNewswire/ -- Am 27. Februar 2017 wandte sich der Systemic Risk Council (SRC) mit einer Grundsatzerklärung an die Finanzminister, Staatsoberhäupter, Finanzchefs und Vorsitzende der Legislativausschüsse der G20-Staaten. „Der SRC hat unsere Ansicht zu den...